

PLURISTEM THERAPEUTICS INC

Form 8-K

March 02, 2009

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **March 2, 2009**

**PLURISTEM THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of incorporation)

**001-31392**

(Commission file number)

**98-0351734**

(I.R.S. Employer Identification Number)

**MATAM Advanced Technology Park**

**Building No. 20**

**Haifa, Israel**

(Address of principal executive offices)

**31905**

(Zip Code)

Registrant's telephone number, including area code: **011 972 74 710 7171**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01 Other Events.**

On March 2, 2009, the registrant issued a press release announcing that the US Food & Drug Administration has cleared the registrant's Investigational New Drug application to initiate a Phase I clinical trial for the treatment of critical limb ischemia using its PLX-PAD product. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release issued by the registrant on March 2, 2009.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PLURISTEM THERAPEUTICS INC.**

Date: March 2, 2009

By: /s/ Yaky Yanay

Yaky Yanay  
Chief Financial Officer

---

---